Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Oncology Hematology Care
mi
from
Cincinnati, OH
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Toledo Community Oncology Program
mi
from
Toledo, OH
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Toledo Community Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Medical University of South Carolina
mi
from
Charlston, SC
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Medical University of South Carolina
mi
from
Charlston, SC
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Family Cancer Center
mi
from
Memphis, TN
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Family Cancer Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Virginia Cancer Institute
mi
from
Richmond, VA
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Status: Enrolling
Updated:  10/23/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Status: Enrolling
Updated: 10/23/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: Enrolling
Updated:  12/16/2013
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: Enrolling
Updated: 12/16/2013
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Duarte, CA
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Loma Linda, CA
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Loma Linda, CA
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Orange, CA
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Orlando, FL
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Detroit, MI
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Portland, OR
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
San Antonio, TX
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Seattle, WA
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
Status: Enrolling
Updated:  1/8/2014
Franklin Square Hospital Center
mi
from
Baltimore, MD
Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
Status: Enrolling
Updated: 1/8/2014
Franklin Square Hospital Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated:  1/20/2014
Dignity Health, St. Joseph's Hospital & Medical Center
mi
from
Phoenix, AZ
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated: 1/20/2014
Dignity Health, St. Joseph's Hospital & Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated:  1/20/2014
Massachusetts General Hospital
mi
from
Boston, MA
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated: 1/20/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated:  1/20/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated: 1/20/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated:  1/20/2014
Vanderbilt University
mi
from
Nashville, TN
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated: 1/20/2014
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
University of Colorado Denver
mi
from
Aurora, CO
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
Moffitt Cancer Center
mi
from
Tampa, FL
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
Massachusetts General Hospital
mi
from
Boston, MA
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
Status: Enrolling
Updated:  1/28/2014
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
Status: Enrolling
Updated: 1/28/2014
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer
A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/4/2014
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer
A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/4/2014
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers
Intervention Development for Anxiety in Metastatic NSCLC Patients and Their Caregivers
Status: Enrolling
Updated:  2/21/2014
Stanford University
mi
from
Stanford, CA
Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers
Intervention Development for Anxiety in Metastatic NSCLC Patients and Their Caregivers
Status: Enrolling
Updated: 2/21/2014
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Baltimore, MD
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Detroit, MI
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Houston, TX
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Fountain Valley, CA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials